iCAGES-guided Precision Therapy for Cancers in Contrast to Standard Care or IHC-guided Theray
Recruiting
Observational Study
Lung Cancer
Gene Abnormality
Gene Product Sequence Variation
Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 – 70
- Sex
- Any
- Study type
- Observational
- Participants needed
- 250 (estimated)
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study prospectively evaluates whether the use of iCAGES (integrated CAncer GEnome Score) tool in guiding the treatment of advanced cancers is superior to current standard care or IHC-guided therapy in progress free survival (PFS),overall survival (OS),and improvement of life quality.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Pathological and clinical diagnosis of recurrence / metastatic lung cancer or other advanced cancers.
* There are PACS images available at the Second Affiliated Hospital of Guangzhou Medical University and the collaborated Hospitals.
* The patient is informed consent and signe…
Contacts